Study wrapper · #1197
Causes and consequences of discontinuation of GLP1RAs or tirzepatide.
Editor's note
Real-world persistence on these drugs is poor, and this review is a careful account of what that gap between prescription and continuation costs patients. Its central caution - that stop-start cycling may carry its own cardiometabolic risk - is framed as a hypothesis, not a demonstrated effect. Directly relevant to our semaglutide and tirzepatide pages, where what happens after stopping is one of the questions readers ask most.
Plain-language abstract
This review examines why many people stop taking GLP-1 receptor agonists such as semaglutide, or the dual agonist tirzepatide, often within the first year - gastrointestinal side effects, less benefit than hoped, high cost, and worry about rare harms - and what follows. Weight regain and deterioration in blood sugar, blood pressure and lipids are common, and the authors raise the possibility that repeated cycles of stopping and restarting add cardiometabolic risk over time. They are explicit that hard outcome data in people who discontinue remain scarce.